摘要
前列腺癌是西方国家发病率最高的恶性肿瘤之一,但是晚期前列腺癌的治疗方案有限,而且仅能延缓疾病的进展,而无法起到治愈的效果。酪氨酸激酶抑制剂靶向作用多种恶性肿瘤取得很好的疗效,并被广泛研究。它可能作为一种治疗晚期前列腺癌的新的治疗策略。本文对酪氨酸激酶抑制剂在转移性趋势抵抗性前列腺癌治疗中的进展做一综述。
Prostate cancer(PCa) is the most prevalent malignancy in western countries. Until recently, there are still few effective therapeutic options available for prostate cancer, and these treatments can only slow down the progress of the disease, but can not cure the disease. TKI has been extensively studied as a treatment for many malignant tumors and may represent a novel strategy for the treatment of advanced prostate cancer. This article reviews the progress of tyrosine kinase inhibitors in the treatment of metastatic castrate resistant prostate cancer.
作者
陈印
李诗娴
董超
CHEN Yin;LI Shi-xian;DONG Chao(Department of Urology, First Affiliated Hospital of Kunming Medical University, Kunming650032, China;Department of General Medicine, Yangpu Hospital of Tongji University, Shanghai 200090, China;Department of the Second Medical Oncology, the Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China)
出处
《肿瘤综合治疗电子杂志》
2019年第2期40-45,共6页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
云南省卫计委医学后备人才培养计划(H-201609)
云南省卫生科技计划项目(2018NS0052)
西山区人才创新项目
关键词
酪氨酸激酶
抑制剂
前列腺癌
Tyrosine kinase
Inhibitor
Prostate cancer
